RxDoctor Payments Data

Patrick Voswinkel, MD

Family Medicine · Duluth, GANPI 1548207442

Payments from drug & device makers

$3,515in general payments, 2019–2025

Across 197 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$457
  • Novo Nordisk$343
  • Merck$302
  • Lilly USA, LLC$218
  • Otsuka America Pharmaceutical, Inc.$142
  • plus $865 from 21 others

What the payments were for

  • Food & beverage$3,515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,515 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$54,758
Medicare patients
147
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$58,191
FarxigaDapagliflozin Propanediol32$38,222
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,807
EliquisApixaban29$19,146
MyrbetriqMirabegron16$13,343
JanuviaSitagliptin Phosphate12$12,360
Lisdexamfetamine Dimesylate20$5,069
ArexvyRsvpref3 Antigen/As01e/Pf18$4,905
BelsomraSuvorexant11$4,655
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,341
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,058
Levothyroxine Sodium179$1,521
Atorvastatin Calcium234$1,321
Testosterone16$1,210
Tamsulosin Hcl85$1,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$343$58,19150 claims
AstraZenecaFarxiga$1,188$38,22232 claims
GSKTrelegy Ellipta, Arexvy$457$24,71239 claims
PfizerEliquis$72$19,14629 claims
MerckJanuvia, Belsomra$302$17,01523 claims
AbbVieSynthroid$51$76012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →